A Phase 2 interventional study of BNT162b2 (Omi XBB.1.5)/RIV and BNT162b2 (Omi XBB.1.5) in Influenza, Human, SARS-CoV-2 Infection and COVID-19, sponsored by Pfizer. Completed at 30 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-30.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Influenza, Human by Pfizer — 1 open to participants now, 2 under way, none of them phase 3. Influenza, Human · Pfizer.
Among the 15 studies in Influenza, Human by Pfizer, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 2, and was the 13th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →1 of the 15 studies in Influenza, Human by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 2 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 644 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 882 across the 11 interventional studies, 5,075 across the 4 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Influenza, Human by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05160636PfizerA Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | 2027-01-31 |
| NCT07431853PfizerA Study to Learn About mRNA Vaccines Against Influenza in Adults | 2027-06-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Influenza, Human by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.
This is a Phase 1/2 study to evaluate the safety, tolerability, and immunogenicity of licensed BNT162b2 (Omi XBB.1.5) and recombinant influenza vaccine (RIV) administered together as a single injection (referred to as BNT162b2 [Omi XBB.1.5]/RIV) in healthy adults 50 years of age or older.
The safety, tolerability, and immunogenicity of BNT162b2 (OmiXBB1.5)/RIV administered as a single injection will be compared to BNT162b2 (Omi XBB.1.5) and RIV administered simultaneously as 2 separate injections (coadministered), and to BNT162b2 (Omi XBB.1.5) or RIV when administered alone.
Across Phases 1 and 2, approximately 640 participants in total will be randomized with an equal randomization ratio to 1 of 4 vaccine groups and stratified by age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single injection combination of BNT162b2 (Omi XBB.1.5) and RIV and normal saline placebo
Biological: BNT162b2 (Omi XBB.1.5)/RIV · Other: Normal saline placebo
Participants will receive BNT162b2 (Omi XBB.1.5) and RIV
Biological: BNT162b2 (Omi XBB.1.5) · Biological: RIV
Participants will receive BNT162b2 (Omi XBB.1.5) and normal saline placebo
Biological: BNT162b2 (Omi XBB.1.5) · Other: Normal saline placebo
Participants will receive RIV and normal saline placebo
Biological: RIV · Other: Normal saline placebo
Drug page: BNT162 Vaccine
Combination of BNT162b2 (Omi XBB.1.5) and RIV
Licensed COVID-19 vaccine
Licensed recombinant influenza vaccine
Normal saline (solution for injection)
Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination
Local reactions included redness, swelling and pain at injection site, recorded by participants in an electronic diary (e-diary). Severity of all local reactions were evaluated as mild, moderate, severe or potentially life-threatening. In this outcome measure local reactions with any severity were reported for each left arm's deltoid and right arm's deltoid of each vaccine Group 1, 2, 3 and 4.
Time frame: Day 1 to Day 7 following Vaccination on Day 1
Percentage of Participants Who Reported Any Systemic Events up to 7 Days Following Vaccination
Systemic events: fever, fatigue, headache, vomiting, diarrhea, chills, new/worsened muscle pain, new/worsened joint pain were recorded by participants in e-diary. Severity of all systemic events were evaluated as mild, moderate, severe or potentially life-threatening. In this outcome measure systemic events with any severity were reported.
Time frame: Day 1 to Day 7 following Vaccination on Day 1
Percentage of Participants Who Reported Any Adverse Events (AEs) From Vaccination Through 4 Weeks After Vaccination
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events collected by systematic assessment (local reactions and systemic events) were excluded from evaluation.
Time frame: From Vaccination on Day 1 through 4 weeks after Vaccination
Percentage of Participants Who Reported Any Serious Adverse Events (SAEs) From Vaccination Through 6 Months After Vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other important medical events per protocol of the study. Events collected by systematic assessment (local reactions and systemic events) were excluded from evaluation.
Time frame: From Vaccination on Day 1 through 6 months after Vaccination
Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron (XBB.1.5)-Neutralizing Titers Before Vaccination
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.
Time frame: Before Vaccination on Day 1
GMTs of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers at 4 Weeks After Vaccination
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.
Time frame: At 4 weeks after Vaccination on Day 1
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers From Before Vaccination to 4 Weeks After Vaccination
GMFR was the ratio of the geometric mean titre values 4 weeks after vaccination to before vaccination. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.
Time frame: From before Vaccination on Day 1 to 4 weeks after Vaccination
Percentages of Participants With Seroresponse to SARS-CoV-2 Omicron (XBB.1.5) at 4 Weeks After Vaccination
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination measure of \>=4\*LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method. As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.
Time frame: At 4 weeks after Vaccination on Day 1
GMTs of Strain Specific Hemagglutinin Inhibition Assay (HAI) Titers Before Vaccination
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMTs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
Time frame: Before Vaccination on Day 1
GMTs of Strain Specific Hemagglutinin Inhibition Assay (HAI) Titers at 4 Weeks After Vaccination
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMTs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
Time frame: At 4 weeks after Vaccination on Day 1
GMFR of Strain Specific HAI Titers From Before Vaccination to 4 Weeks After Vaccination
GMFR was the ratio of the geometric mean titre values 4 weeks after vaccination to before vaccination. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMFRs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
Time frame: From before Vaccination to 4 weeks after Vaccination on Day 1
Percentages of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination
Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a minimum 4-fold rise at the time point of interest. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated seroconversion of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
Time frame: At 4 weeks after Vaccination on Day 1
Percentages of Participants With HAI Titers >= 1:40 Before Vaccination
Percentages of participants with HAI titers \>= 1:40 before vaccination along with the associated 2-sided 95% CIs, was provided for each vaccine group in this outcome measure. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
Time frame: Before Vaccination on Day 1
Percentages of Participants With HAI Titers >= 1:40 at 4 Weeks After Vaccination
Percentages of participants with HAI titers \>= 1:40 at 4 weeks after vaccination along with the associated 2-sided 95% CIs, was provided for each vaccine group in this outcome measure. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As outcome measure evaluated of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
Time frame: At 4 Weeks after Vaccination on Day 1
| Milestone | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo |
|---|---|---|---|---|
| Started | 160 | 163 | 160 | 161 |
| Vaccinated | 160 | 161 | 160 | 160 |
| Completed | 145 | 155 | 151 | 151 |
| Not completed | 15 | 8 | 9 | 10 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 11 | 5 | 8 | 8 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 | 1 | 0 |
Local reactions included redness, swelling and pain at injection site, recorded by participants in an electronic diary (e-diary). Severity of all local reactions were evaluated as mild, moderate, severe or potentially life-threatening. In this outcome measure local reactions with any severity were reported for each left arm's deltoid and right arm's deltoid of each vaccine Group 1, 2, 3 and 4.
| Percentage of participants | Group 1, BNT162b2/RIV + Placebo: BNT162b2/RIV | Group 1, BNT162b2/RIV + Placebo: Placebo | Group 2, BNT162b2 + RIV: BNT162b2 | Group 2, BNT162b2 + RIV: RIV | Group 3, BNT162b2 + Placebo: BNT162b2 | Group 3, BNT162b2 + Placebo: Placebo | Group 4, RIV + Placebo: RIV | Group 4, RIV + Placebo: Placebo |
|---|---|---|---|---|---|---|---|---|
| Pain at injection site | 56.3 (48.2 to 64.1) | 11.9 (7.3 to 17.9) | 59.0 (51.0 to 66.7) | 38.5 (31.0 to 46.5) | 62.5 (54.5 to 70.0) | 9.4 (5.3 to 15.0) | 36.9 (29.4 to 44.9) | 8.1 (4.4 to 13.5) |
| Redness | 8.8 (4.9 to 14.2) | 1.3 (0.2 to 4.4) | 5.0 (2.2 to 9.6) | 3.1 (1.0 to 7.1) | 5.0 (2.2 to 9.6) | 0.6 (0.0 to 3.4) | 6.3 (3.0 to 11.2) | 0.6 (0.0 to 3.4) |
| Swelling | 9.4 (5.3 to 15.0) | 1.3 (0.2 to 4.4) | 6.2 (3.0 to 11.1) | 3.1 (1.0 to 7.1) | 5.6 (2.6 to 10.4) | 0.6 (0.0 to 3.4) | 5.0 (2.2 to 9.6) | 0.6 (0.0 to 3.4) |
Systemic events: fever, fatigue, headache, vomiting, diarrhea, chills, new/worsened muscle pain, new/worsened joint pain were recorded by participants in e-diary. Severity of all systemic events were evaluated as mild, moderate, severe or potentially life-threatening. In this outcome measure systemic events with any severity were reported.
| Percentage of participants | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo |
|---|---|---|---|---|
| Fever | 1.9 (0.4 to 5.4) | 6.2 (3.0 to 11.1) | 6.3 (3.0 to 11.2) | 0 (0.0 to 2.3) |
| Fatigue | 36.3 (28.8 to 44.2) | 39.1 (31.5 to 47.1) | 40.6 (32.9 to 48.7) | 33.1 (25.9 to 41.0) |
| Headache | 24.4 (17.9 to 31.8) | 31.1 (24.0 to 38.8) | 26.9 (20.2 to 34.4) | 16.9 (11.4 to 23.6) |
| Vomiting | 0 (0.0 to 2.3) | 3.1 (1.0 to 7.1) | 1.9 (0.4 to 5.4) | 0 (0.0 to 2.3) |
| Diarrhea | 8.1 (4.4 to 13.5) | 11.2 (6.8 to 17.1) | 11.3 (6.8 to 17.2) | 7.5 (3.9 to 12.7) |
| Chills | 8.8 (4.9 to 14.2) | 14.9 (9.8 to 21.4) | 15.0 (9.9 to 21.5) | 6.9 (3.5 to 12.0) |
| New or worsened muscle pain | 13.1 (8.3 to 19.4) | 22.4 (16.2 to 29.6) | 15.0 (9.9 to 21.5) | 8.1 (4.4 to 13.5) |
| New or worsened joint pain | 7.5 (3.9 to 12.7) | 13.7 (8.8 to 20.0) | 10.0 (5.8 to 15.7) | 4.4 (1.8 to 8.8) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events collected by systematic assessment (local reactions and systemic events) were excluded from evaluation.
| Percentage of participants | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Reported Any Adverse Events (AEs) From Vaccination Through 4 Weeks After Vaccination | 4.4 (1.8 to 8.8) | 3.7 (1.4 to 7.9) | 5.6 (2.6 to 10.4) | 5.6 (2.6 to 10.4) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other important medical events per protocol of the study. Events collected by systematic assessment (local reactions and systemic events) were excluded from evaluation.
| Percentage of participants | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Reported Any Serious Adverse Events (SAEs) From Vaccination Through 6 Months After Vaccination | 1.9 (0.4 to 5.4) | 0.6 (0.0 to 3.4) | 0 (0.0 to 2.3) | 1.9 (0.4 to 5.4) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.
| Titer | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo |
|---|---|---|---|
| Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron (XBB.1.5)-Neutralizing Titers Before Vaccination | 311.2 (236.2 to 409.9) | 285.4 (220.4 to 369.5) | 338.5 (256.9 to 446.0) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.
| Titer | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo |
|---|---|---|---|
| GMTs of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers at 4 Weeks After Vaccination | 2162.4 (1719.6 to 2719.4) | 2581.3 (2076.2 to 3209.5) | 3644.7 (2853.7 to 4654.8) |
GMFR was the ratio of the geometric mean titre values 4 weeks after vaccination to before vaccination. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.
| Ratio | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo |
|---|---|---|---|
| Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers From Before Vaccination to 4 Weeks After Vaccination | 6.1 (4.7 to 7.9) | 8.0 (6.3 to 10.1) | 9.4 (7.2 to 12.3) |
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination measure of \>=4\*LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method. As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.
| Percentage of participants | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo |
|---|---|---|---|
| Percentages of Participants With Seroresponse to SARS-CoV-2 Omicron (XBB.1.5) at 4 Weeks After Vaccination | 53.7 (45.3 to 61.9) | 60.5 (52.4 to 68.2) | 63.8 (55.6 to 71.4) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMTs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
| Titer | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 4: RIV + Placebo |
|---|---|---|---|
| A/Victoria/4897/ 2022 (H1N1) HAI | 43.8 (33.9 to 56.5) | 60.7 (47.7 to 77.1) | 62.6 (49.0 to 79.8) |
| A/Darwin/9/ 2021 (H3N2) HAI | 34.8 (26.8 to 45.1) | 42.3 (32.7 to 54.9) | 44.3 (33.8 to 58.1) |
| B/Michigan/1/ 2021 HAI | 105.9 (82.4 to 136.2) | 101.8 (81.4 to 127.4) | 114.9 (92.0 to 143.6) |
| B/Phuket/3073/ 2013 HAI | 186.6 (151.8 to 229.5) | 218.5 (181.3 to 263.2) | 228.8 (185.9 to 281.7) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMTs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
| Titer | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 4: RIV + Placebo |
|---|---|---|---|
| A/Victoria/4897/ 2022 (H1N1) HAI | 324.4 (250.4 to 420.2) | 374.7 (299.4 to 469.1) | 389.6 (309.4 to 490.5) |
| A/Darwin/9/ 2021 (H3N2) HAI | 397.7 (310.4 to 509.7) | 489.7 (393.9 to 608.9) | 557.2 (440.8 to 704.2) |
| B/Michigan/1/ 2021 HAI | 464.0 (384.5 to 559.9) | 427.5 (360.0 to 507.6) | 496.0 (408.6 to 602.1) |
| B/Phuket/3073/ 2013 HAI | 669.7 (568.4 to 789.0) | 769.5 (658.9 to 898.7) | 775.7 (656.1 to 917.1) |
GMFR was the ratio of the geometric mean titre values 4 weeks after vaccination to before vaccination. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMFRs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
| Ratio | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 4: RIV + Placebo |
|---|---|---|---|
| A/Victoria/4897/ 2022 (H1N1) HAI | 6.6 (5.2 to 8.5) | 5.7 (4.5 to 7.2) | 5.7 (4.5 to 7.2) |
| A/Darwin/9/ 2021 (H3N2) HAI | 9.9 (7.7 to 12.6) | 10.1 (8.0 to 12.8) | 11.0 (8.5 to 14.3) |
| B/Michigan/1/ 2021 HAI | 4.3 (3.5 to 5.3) | 4.1 (3.4 to 5.0) | 4.2 (3.3 to 5.4) |
| B/Phuket/3073/ 2013 HAI | 3.6 (2.9 to 4.4) | 3.5 (2.9 to 4.2) | 3.4 (2.8 to 4.1) |
Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a minimum 4-fold rise at the time point of interest. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated seroconversion of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
| Percentage of participants | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 4: RIV + Placebo |
|---|---|---|---|
| A/Victoria/4897/ 2022 (H1N1) HAI | 62.7 (54.6 to 70.4) | 67.7 (59.8 to 74.9) | 61.3 (53.1 to 69.0) |
| A/Darwin/9/2021 (H3N2) | 76.5 (68.9 to 82.9) | 79.1 (71.9 to 85.2) | 76.1 (68.6 to 82.6) |
| B/Michigan/1/2021 | 54.9 (46.7 to 62.9) | 53.2 (45.1 to 61.1) | 51.0 (42.8 to 59.1) |
| B/Phuket/3073/2013 | 49.7 (41.5 to 57.9) | 53.8 (45.7 to 61.8) | 46.5 (38.4 to 54.6) |
Percentages of participants with HAI titers \>= 1:40 before vaccination along with the associated 2-sided 95% CIs, was provided for each vaccine group in this outcome measure. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
| Percentage of participants | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 4: RIV + Placebo |
|---|---|---|---|
| A/Victoria/4897/ 2022 (H1N1) HAI | 55.6 (47.3 to 63.6) | 69.6 (61.8 to 76.7) | 70.3 (62.5 to 77.4) |
| A/Darwin/9/2021 (H3N2) | 49.7 (41.5 to 57.9) | 57.6 (49.5 to 65.4) | 54.8 (46.7 to 62.8) |
| B/Michigan/1/2021 | 74.5 (66.8 to 81.2) | 81.6 (74.7 to 87.3) | 81.3 (74.2 to 87.1) |
| B/Phuket/3073/2013 | 89.5 (83.6 to 93.9) | 94.3 (89.5 to 97.4) | 93.5 (88.5 to 96.9) |
Percentages of participants with HAI titers \>= 1:40 at 4 weeks after vaccination along with the associated 2-sided 95% CIs, was provided for each vaccine group in this outcome measure. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As outcome measure evaluated of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.
| Percentage of participants | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 4: RIV + Placebo |
|---|---|---|---|
| A/Victoria/4897/ 2022 (H1N1) HAI | 90.8 (85.1 to 94.9) | 95.6 (91.1 to 98.2) | 96.8 (92.6 to 98.9) |
| A/Darwin/9/2021 (H3N2) | 95.4 (90.8 to 98.1) | 97.5 (93.6 to 99.3) | 96.1 (91.8 to 98.6) |
| B/Michigan/1/2021 | 98.0 (94.4 to 99.6) | 100.0 (97.7 to 100.0) | 99.4 (96.5 to 100.0) |
| B/Phuket/3073/2013 | 99.3 (96.4 to 100.0) | 100.0 (97.7 to 100.0) | 100.0 (97.6 to 100.0) |
Collected over AEs by systematic assessment: Day 1 up to 7 Days following Vaccination; AEs by Non-systematic assessment: a) Serious AEs- Day 1 of Vaccination up to 6 months of follow-up after Vaccination, b) Other AEs- Day 1 of Vaccination up to 4 weeks of follow-up after Vaccination; All-cause mortality: Day 1 of Vaccination up to 6 months of follow-up after Vaccination. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | 0/160 (0%) | 3/160 (1.9%) | 114/160 (71.3%) |
| Group 2: BNT162b2 (Omi XBB.1.5) + RIV | 0/161 (0%) | 1/161 (0.6%) | 117/161 (72.7%) |
| Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | 0/160 (0%) | 0/160 (0%) | 115/160 (71.9%) |
| Group 4: RIV + Placebo | 1/160 (0.6%) | 3/160 (1.9%) | 88/160 (55%) |
| Event | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo |
|---|---|---|---|---|
| DeathGeneral disorders | 0/160 | 0/161 | 0/160 | 1/160 |
| AppendicitisInfections and infestations | 1/160 | 0/161 | 0/160 | 0/160 |
| Infected skin ulcerInfections and infestations | 1/160 | 0/161 | 0/160 | 0/160 |
| Localised infectionInfections and infestations | 0/160 | 0/161 | 0/160 | 1/160 |
| Urinary tract infectionInfections and infestations | 0/160 | 0/161 | 0/160 | 1/160 |
| Metastatic squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/160 | 0/161 | 0/160 | 1/160 |
| Transient ischaemic attackNervous system disorders | 1/160 | 0/161 | 0/160 | 0/160 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/160 | 0/161 | 0/160 | 1/160 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/160 | 0/161 | 0/160 | 1/160 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/160 | 0/161 | 0/160 | 1/160 |
| Event | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo |
|---|---|---|---|---|
| Injection site pain (PAIN AT THE INJECTION SITE) left deltoidGeneral disorders | 90/160 | 95/161 | 100/160 | 59/160 |
| Fatigue (FATIGUE)General disorders | 58/160 | 63/161 | 65/160 | 53/160 |
| Injection site pain (PAIN AT THE INJECTION SITE) right deltoidGeneral disorders | 19/160 | 62/161 | 15/160 | 13/160 |
| Headache (HEADACHE)Nervous system disorders | 39/160 | 50/161 | 43/160 | 27/160 |
| Myalgia (NEW OR WORSENED MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 21/160 | 36/161 | 24/160 | 13/160 |
| Chills (CHILLS)General disorders | 14/160 | 24/161 | 24/160 | 11/160 |
| Arthralgia (NEW OR WORSENED JOINT PAIN)Musculoskeletal and connective tissue disorders | 12/160 | 22/161 | 16/160 | 7/160 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 13/160 | 18/161 | 18/160 | 12/160 |
| Injection site swelling (SWELLING) left deltoidGeneral disorders | 15/160 | 10/161 | 9/160 | 8/160 |
| Injection site erythema (REDNESS) left deltoidGeneral disorders | 14/160 | 8/161 | 8/160 | 10/160 |
Safety analysis set (SAS) consisted of all participants who received at least 1 dose of the study intervention.
| Age, Continuous(Years) | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo | Total |
|---|---|---|---|---|---|
| Mean | 63.9 ± 8.40 | 63.9 ± 9.06 | 62.9 ± 7.73 | 63.9 ± 7.66 | 63.7 ± 8.22 |
| Sex: Female, Male(Participants) | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo | Total |
|---|---|---|---|---|---|
| Female | 87 | 92 | 100 | 83 | 362 |
| Male | 73 | 69 | 60 | 77 | 279 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 28 | 28 | 29 | 21 | 106 |
| Not Hispanic or Latino | 132 | 133 | 131 | 137 | 533 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo | Group 2: BNT162b2 (Omi XBB.1.5) + RIV | Group 3: BNT162b2 (Omi XBB.1.5) + Placebo | Group 4: RIV + Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 1 | 1 | 4 |
| Asian | 5 | 6 | 3 | 6 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 2 | 4 |
| Black or African American | 37 | 38 | 30 | 30 | 135 |
| White | 117 | 111 | 124 | 117 | 469 |
| More than one race | 0 | 2 | 2 | 2 | 6 |
| Unknown or Not Reported | 1 | 0 | 0 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2024 to primary completion in Sep 2024, 7 months.
Results were first posted in Sep 2025, 1 year after primary completion.
Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 7 months is close to that.
Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine